Merdury Biopharmaceutical

Merdury Biopharmaceutical Interest Coverage

The Interest Coverage Ratio of Merdury Biopharmaceutical (6932.TWO) as of Oct 19, 2026 is -15.38. In the previous year, Interest Coverage Ratio was -18.28 — a change of -15.87% (higher).

Interest Coverage

-15.38

YoY

-15.87%

Last updated:

Interest Coverage Ratio of Merdury Biopharmaceutical is 2024 -15.38 . Interest Coverage Ratio of Merdury Biopharmaceutical was 2023 -18.28 . It decreases by -15.87% higher compared to the previous year.

The Merdury Biopharmaceutical Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2021
-529.80 TWD
Jan 1, 2022
-428.47 TWD
Jan 1, 2023
-18.28 TWD
Jan 1, 2024
-15.38 TWD
The Merdury Biopharmaceutical Interest Coverage history
YEARInterest CoverageYoY
-15.38-15.87%
-18.28-95.73%
-428.47-19.13%
-529.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

Interest Coverage Ratio of Merdury Biopharmaceutical is -15.38 in 2024.

Interest Coverage Ratio of Merdury Biopharmaceutical changed from -18.28 to -15.38, representing a -15.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical